US Stock MarketDetailed Quotes
TELO Telomir Pharmaceuticals
- 5.200
- +0.110+2.16%
Close Dec 13 16:00 ET
- 5.200
- 0.0000.00%
Post 20:01 ET
153.97MMarket Cap-6.71P/E (TTM)
5.350High4.350Low532.62KVolume4.690Open5.090Pre Close2.51MTurnover3.05%Turnover RatioLossP/E (Static)29.61MShares20.72052wk High346.67P/B90.82MFloat Cap3.11052wk Low--Dividend TTM17.46MShs Float20.720Historical High--Div YieldTTM19.65%Amplitude3.110Historical Low4.712Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Telomir Pharmaceuticals Stock Forum
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price
Thursday, 12th December at 8:30 am
Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth potential.
MIAMI, FL / ACCESSWIRE / December 12, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) ("Telomir" or the "Company"...
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares. Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$ PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...
The transaction did not involve the issuance of any warrants. This transaction follows a $5 million non-dilutive line of credit extende...
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Telomir Pharmaceuticals (NASDAQ:TELO) has been featured in a local ABC exclusive highlighting promising age reversal outcomes in two senior dogs using their novel small molecule, Telomir-1. The compassionate use program, observed by Dr. Michael Roizen, showed remarkable improvements in the dogs' health and vitality. Zeus, a 12-year-old Ger...
NEWS
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir Pharmaceuticals presents promising pre-clinical data on Telomir-1 at a National Press Club event, showcasing a 40% increase in telomerase activity and lengthening of telomeres in human cells. The company plans to initiate human clinical trials for osteoarthritis and veterinary trials in 2025 after pre-clinical...
No comment yet